Formation of dsRNA by-products during in vitro transcription can be reduced by using low steady-state levels of UTP

Introduction: Exogeneous messenger ribonucleic acid (mRNA) can be used as therapeutic and preventive medication. However, during the enzymatic production process, commonly called in vitro transcription, by-products occur which can reduce the therapeutic efficacy of mRNA. One such by-product is doubl...

Full description

Bibliographic Details
Main Authors: Thomas Ziegenhals, Ronja Frieling, Philipp Wolf, Katharina Göbel, Stina Koch, Mia Lohmann, Markus Baiersdörfer, Stephanie Fesser, Ugur Sahin, Andreas N. Kuhn
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1291045/full